1. Lefkowitch JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res 2007; 38: 634-43. doi: 10.1016/j.arcmed.2006.08.005.
2. Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A from E: A critical review of viral hepatitis. Worl J Gastroenterol 2021; 27:1691-1715. doi:10.3748/wjg.v27.
i16.1691
3. Krishna M. Histological grading and staging of chronic hepatitis. Clin Liver Dis (Hoboken) 2021; 17: 222-226.
4. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver disease: a synopsis. Clin Exp Med 2023; 23:273-285.
5. European Association fort he Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virüs infection. J Hepatol 2017;67:370-98.
6. Korkmaz P, Demirturk N, Batırel A et al. Noninvazive models to predict liver fibrosis in patients with chronic hepatitis B: Study from Turkey. Hepat Mon 2017;17:12:e60266.
7. Global hepatitis report, 2017. World Health Organization (WHO). (erişim tarihi: 29.11.2023). https://iris.who.int/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1
8. Global health sector strategies on, respectively HIV, viral hepatitis and sexually transmitted infections fort he period 2022-2030. World Health Organization (WHO). (erişim tarihi: 29.11.2023).
https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf?sequence=1.
9. Hepatitis B. World Health Organization (WHO). (erişim tarihi: 27.11.2023). https:/www.who.int/news-room/fact-sheets/detail/hepatitis-b.
10. Tozun N, Ozdogan O, Cakaloglu Y et al. Seroprevalence of hepatitis B and C virüs infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6.
11. Demirtürk N, Köse A, Ural O ve ark Kronik hepatit B enfeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Rapo-
ru-2023 Güncellemesi. KLİMİK Derg 2023; 36:1-22.
12. Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet 2023; 401:1039-52.
13. Tülek N. Hepatit B enfeksiyonlarının immünopatogenezi Flora 2019;24:1-10.
14. Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis and treatment of chronic hepatitis B: AASLD 2018 Hepatiti B guidance . Hepatology 2018; 67:1560-99.
15. Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virüs infection. Clin Mol Hepatol 2023; 29:605-22.
16. Evon DM, Lin HS, Fontana RJ et al. Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis
B. Gastrohep 2021;3:196-208.
17. Cacoub P, Asselah T. Hepatitis B virüs infect,on and extra-hepatic manifestations: A systemic disease. AM J Gastroenterol 2022;117:253-263.
18. Cornberg M, Lok ASF, Terrault NA, Zoulim F. 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. J Hepatol 2020;72:539-557.
19. SH A, Kim W, Jung YK et al. Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disproxil fumarat in treatment oh chronic hepatitis B virüs infection. Clin Gasroenterol
Hepatol 2019; 17:1850-59.
20. Opio CK, Lee WM, Kirkpatrick P. Entecavir Net Rev Drug Discov 2005;4:535-6.
21. Hwang EG, Jung EA, Yoo JJ, Kim SG, Kim YS. Rsik of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamid: a systematic review and meta-analysis. Hepatol Int 2023;17:860-
9.
22. Bömmel F v, Berg T. Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B. Hepatology Com-
munications 2021;5(10): 1632-48.
23. Tekin S, Karakeçili F, Binay UD ve ark. Özel hasta gruplarında kronik hepatit B yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı
raporu- 2023 Güncelleme. KLİMİK Derg 2023;36(özel sayı-1):23-41.
24. Belopolskaya M, Avrutin V, Kalinina O, Dmitriev A, Gusec D. Chronic hepatitis B in pregnant women: Current trends and approaches. World J Gastroenterol 2021; 27(23):3279-3289.
25. Brunetto MR, Ricco G, Negro F et al. European Association for the Study of the Liver (EASL) Clinical practice guidelines on hepatitis delta virüs. J Hepatol 2023;79(2):433-460.
26. Yardeni D, Heller T, Koh C. Chronic hepatitis D: What is change? J Viral Hepat 2022;29(4):240-251.
27. Ayaz C, Yardımcı C, Çandır N ve ark. Kronik Hepatit D Virüsu İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral hepatit Çalışma Grubu Uzlaşı
raporu KLİMİK Derg 2014;27(Supp-1):40-7.
28. Değertekin H, Yalçın K, Yakut M, Yurdaydın C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008;28(4):494-8.
29. Yurdaydın C. Kronik hepatit delta enfeksiyonunun bugünü ve yarını. In: Boyacıoğlu S (ed). Kronik Hepatitler B, C, Delta 2014 ve sonrası. 1. Baskı, Fersa Matbaacılık, Ankara, 2014, p: 101-110.
30. Pearlman B. Hepatitis Delta Infection: a clinical review. Semin Liver Dis 2023;43:293-304.
31. T.C. Sağlık Bakanlığı, Halk Sağlığı genel Müdürlüğü. Türkiye Viral Hepatit Önleme ve Kontrol Programı (2018-2023). (erişim tarihi: 07.01.2024). avaible at: https://hsgm.saglik.gov.tr/depo/
Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf.
32. Idılman Razavi H, Robbins-Scott S et al. A micro-elemination approach to addressing hepatitis C in Turkey. BMC health Services Researches 2020;20:249.
33. World Health Organization. Combating hepatitis B and C to reach elemination by 2030. May 2016. Avaible at: https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-rea-
ch-elimination-by-2030 (erişim tarihi: 29.03.2024).
34. World Health Organization. Guidance for country validation of viral hepatitis elimination and path to elemination, 2023. avaible at: https://reliefweb.int/report/world/guidance-country-vali-
dation-viral-hepatitis-elimination-and-path-elimination?gad_source=1&gclid=Cj0KCQiAtOmsBhCnARIsAGPa5ybtN9mvANVSfiuYbQprSaoO_aU9PlVtebcUr84e80LXGGzgJgYeutgaAk-
FMEALw_wcB (erişim tarihi: 29.03.2024).
35. Türkiye Cumhuriyeti Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü. Türkiye Viral Hepatit Önleme ve Kontrol Programı (2018-2023). (erişim tarihi: 07.01.2024). avaible at: https://hsgm.
saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf.
36. Aygen B, Gürbüz Y, Çetinkaya RA ve ark. Kronik hepatit C enfeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Ra-
poru-2023 Güncellemesi. KLİMİK Derg 2023; 36 (özel sayı-1):43-75.
37. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virüs infection. Avaible at:https://www.who.int/publications-detail-redire-
ct/9789241550345. Erişim tarihi: 29.03.2024.
38. Flores-Chávez A, Carrion JA, Forns X, Ramos-Casals M.Extrahepatic manifestations associated with chronic hepatitis C virüs infection. Rev Esp Sanid Penit 2017;19:87-97.
39. Mazzaro C, Quartuccio L, Adinolfi LE et al. A review of extrahepatic manifestations of chronic hepatitis C virüs infection and the impact of direct-acting antiviral therapy. Virüses
2021;13(11).2249. doi:10.3390/v13112249.
40. European Association fort he Study of the Liver. EASL recommendation on treatment of hepatitis C: Final update of the series. J Hepatol 2020;73(5):1170-1218.
41. World Health Organization. Guidelines on hepatitis B and C testing. Genova, 2017. Avaible at: https://www.who.int/publications/i/item/9789241549981. Erişim tarihi: 30.03.2024.
42. Gonzalez-Grande R, Jimenez-perez M, Arjona CG,Torres JM. New approaches in the treatment of hepatitis C. Worl J Gastroenterol 2016;22(4):1421-32.
43. Murray M. Mechanism and clinical significance of pharmacokinetic drug interactions mediated by FDA and EMA-approved Hepatitis C direct-acting antiviral agents. Clin Pharmacokinet
2023;62(10):1365-1392.
44. Demirturk N, Aygen B, Celik İ et al. Real World data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment fpr chronic hepatitis C really effective? Turk J Gastroentero
2021;32(2):155-163.
45. Aygen B, Demirturk N, Yıldız O et al. Real-world efficacy, safety and clinical outcomes of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin combination therapy in patients with hepa-
titis C virüs genotype 1 or 4 infection: The Turkey experience. Turk J Gastroenterol 2020;31(4):305-317.
46. Ghany MG. AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virüs Infection.
Hepatology 2020;71(2):686-721.
47. European AIDS Clinicak Society. EACS Guidelines Version 11.1, 2022. Avaible at: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf. Erişim tarihi: 31.03.2024.
48. European Association fort he Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virüs infection. J Hepatol 2018;68(6):1256-71.
49. Ma Z, A de Man R, Kamar N, Pan Q. Chronic hepatitis E:Advancing research and patients care. J Hepatol 2022; 77(4):1109-1123.
50. Murali AR, Kotwal V, Chawla S. Chronic hepatitis E: A brief review. World J Hepatol 2015; 7(19):194-201.
51. Alexandrova M, Tsachev I, Kirov P et al. Hepatitis E Virüs (HEV) infection among immunocompromised individuals:A brief narrative review. Infect Drug Resist 2024;17:1021-1040.
52. Kamar N, Izopet J, Tripon S et al. Ribavirin for chronic hepatitis E virüs infection in transplant recipients. N Engl J Med 2014;370(12):1111-20